Landmark PRIME Study Shows PreTRM® Test Significantly Reduces Preterm Births and Neonatal Complications

summarizeSummary

Sera Prognostics reported landmark clinical trial results for its PreTRM® blood test, showing significant reductions in preterm births and improved newborn health outcomes.

check_boxKey Events

• Landmark PRIME Study Results Published

  Sera Prognostics announced the publication of positive results from its PRIME study in the Pregnancy Journal, demonstrating the effectiveness of its PreTRM® blood test.

• Significant Reduction in Preterm Births

  The study showed a 56% reduction in babies born before 32 weeks and a 32% reduction before 35 weeks when using the PreTRM® test with targeted interventions.

• Improved Neonatal Outcomes

  Key findings include a 20% reduction in NICU admissions and a 20% decrease in neonatal morbidity, saving one NICU day for every 4.2 patients screened.

• Jefferies Fireside Chat Scheduled

  Company executives will discuss the full PRIME study results during a Jefferies-hosted fireside chat on January 9, 2026.

auto_awesomeAnalysis

Sera Prognostics announced highly positive results from its landmark PRIME study, published in the Pregnancy Journal. The PreTRM® blood test, combined with targeted interventions, demonstrated a substantial reduction in early preterm births and improved neonatal outcomes. These findings significantly strengthen the clinical evidence for the PreTRM® test-and-treat strategy, potentially expanding its market adoption and value proposition. The upcoming fireside chat with Jefferies will provide further details and insights into these transformative results, which could materially impact the company's commercial trajectory and address a critical unmet medical need.